Evidence map›Paper›PMID 32029346›Full record

ArticleInternational journal of radiation oncology, biology, physics2020

Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.

Jianqing Lin, Robert B Den, Jacob Greenspan, Timothy N Showalter, Jean H Hoffman-Censits, Costas D Lallas, Edouard J Trabulsi, Leonard G Gomella, Mark D Hurwitz, Benjamin Leiby and 2 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jianqing LinDepartment of Medical Oncology, George Washington University, Washington, District of Columbia.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: Robert.den@jefferson.edu.
Jacob GreenspanDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Timothy N ShowalterDepartment of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, Virginia.
Jean H Hoffman-CensitsDepartment of Medical Oncology, Department of Medical Oncology, Johns Hopkins University, Baltimore, Maryland.
Costas D LallasDepartment of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Edouard J TrabulsiDepartment of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Leonard G GomellaDepartment of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Mark D HurwitzDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Benjamin LeibyDepartment of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, Philadelphia, Pennsylvania.
Adam P DickerDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
W Kevin KellyDepartment of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Thomas Jefferson University · USGeorge Washington University · USJohns Hopkins University · USUniversity of Virginia · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
NCI NIH HHS P30 CA056036
6 · The paper itself

Abstract

purposeCabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer. METHODS AND MATERIALS: Twenty men were enrolled in this institutuional review board-approved phase I clinical trial using a 3 + 3 design. Patients were followed prospectively for safety, efficacy, and health-related quality of life (Expanded Prostate Index Composite). Efficacy was assessed biochemically using the Phoenix definition.

resultsWith a median follow-up time of 56 months, the maximum tolerated dose of concurrent cabazitaxel was 6 mg/m

conclusionsThis is the first clinical trial of prostate cancer to report on the combination of cabazitaxel and radiation therapy. The maximum tolerated dose of concurrent cabazitaxel with radiation and androgen deprivation therapy was determined to be 6 mg/m

Indexed as

Radiotherapy, Intensity-ModulatedAgedAged, 80 and overAndrogen AntagonistsCombined Modality TherapyDose-Response Relationship, DrugDose-Response Relationship, RadiationDrug Administration ScheduleHumansMaleMiddle AgedNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantQuality of Health CareSafetyTaxoidsAndrogen AntagonistscabazitaxelTaxoids

Identifiers

PMID32029346
PMCPMC8186272
OpenAlexW3005195957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.